Collaborating to improve quality of life in primary immunodeficiencies: World PI Week, 2013

Ricardo Sorensen M.D., 1 Amos Etzioni, M.D., 2 Ahmed Aziz Bousfiha, M.D., 3 John B. Zeiger, M.D. 4

1. Department of Paediatrics Children's Hospital, 200 Henry Clay Ave. New Orleans, LA, USA

2. Meyer Children's Hospital, Haifa, Israel

3. Clinical Immunology Unit, King Hassan II University, Averroes Hospital, Casablanca, Morocco

4. Sydney Children’s Hospital, Randwick, New South Wales, Australia

Corresponding author: Ricardo Sorensen M.D.

Type of article: Scientific editorial
Introduction

World Primary Immunodeficiency Week (WPIW) 2013 runs from 22–29th April (www.worldpiweek.org). As this celebration and awareness campaign approaches, it is time to reflect on progress made and the challenges that remain for the primary immunodeficiency diseases (PID) community. In this article, representatives from leading PID societies evaluate the situation and plans for further progress in their respective areas of the world. It is hoped that this situation analysis will prompt further focus and enhanced collaboration on the gaps that remain in the pursuit of promoting early diagnosis and treatment of PIDs.

Europe

The European Society for Primary Immunodeficiency (ESID) is the oldest and largest professional organization focused on PIDs. Currently ESID has 800 members and almost 2000 individuals attended its last biennial meeting (Florence, October 2012).

ESID developed the first clinical database for PIDs. Containing data from over 10,000 patients, this large registry has been used for many important projects and published studies.1−3 Furthermore, in 2012, ESID members collaborated in the publication of an updated PID diagnostic protocol for non-immunologists. This protocol incorporates newly defined PIDs and is designed to assist physicians caring for adults and children to promptly and cost-effectively screen and diagnose PIDs based on the clinical presentation and laboratory tests, with definitive tests subsequently performed in partnership with specialist immunologists.4

Aside from organizing the biennial meeting, ESID is involved in many other educational activities, such as a summer school for PID. A major objective of the organization is to increase awareness of PID through a new website and meetings with patient organizations. ESID also supports the wonderful ‘J project’, conducted by Prof. László Maródi (Hungary), which aims to develop PID awareness and expertise in eastern and central European countries.5
In the upcoming year, ESID will focus on two main points for Europe:

- Implementation of neonatal screening for severe combined immunodeficiency (SCID). After the success of the program in several states in the USA, ESID will push for SCID screening to be established soon in many European countries.

- Provision of adequate treatment of the various PIDs across Europe. Unfortunately, in many countries the supply of intravenous immunoglobulin (IVIG) is inadequate and haematopoietic stem cell transplantation (HSCT) centres have yet to be developed in some countries, mainly in eastern Europe.

Although much has been achieved, there is still a long way to go in providing the early and precise diagnosis of PID, together with the appropriate treatment, to the many thousands of patients all over Europe and the world.

**Latin America**

Organised efforts towards improving the diagnosis and management of patients with PIDs in Latin America started in 1993 when a small group of immunologists from Argentina, Brazil, Chile and Colombia teamed up with Ricardo Sorensen, M.D., in the USA to create a joint patient reporting form under the auspices of an informal group called the Latin American Group for Primary Immunodeficiencies (LAGID). The goals of this organization were to include other Latin American countries and to create registries of patients with PIDs in each participating country. The group grew from the initial four to a total of 14 countries with a wide population range.

Many of the objectives set forth by LAGID have been accomplished, including: the development of patient and parent support groups in most participating countries; the creation of a website for members; the organization of 12 yearly scientific meetings held from 1995 to 2007; educational programmes and the education of paediatricians and general practitioners; and extensive collaborative efforts between member countries and between Latin American immunologists and their colleagues in Europe and the US. These efforts led to the creation of the first joint PID registry published by eight countries in 1998. A second report was published in 2007.
A second official electronic registry, following the model of the ESID registry, was established for all of Latin America in Sao Paulo, Brazil, with the assistance of ESID. Other actions have contributed to advancing the care of patients with PID in Latin America and have brought a new dynamic to diagnosis, treatment and research in the region.\textsuperscript{8,9} These actions include the sponsored fellowship programme led by the Latin American Society for Immunodeficiencies (LASID), founded in 2009, which has assisted young immunologist in five countries to specialise in the diagnosis and care of PID, and the establishment of a network of Jeffrey Modell Diagnostic and Research Centers in Sao Paulo, Mexico City, Medellin, Chile and Buenos Aires. Created by the Jeffrey Modell Foundation, these centres offer enhanced diagnostic and treatment capabilities for PID across the world, including now in Latin America. Health authorities in several countries, including Mexico, Colombia, Argentina, Brazil and Chile, have now recognised PIDs as a special group of diseases and facilitated access to treatment.

The present day challenges of PID in Latin America are two-fold: to continue to expand awareness and diagnosis and treatment possibilities to more areas in Latin America where there has been little or no progress, and to satisfy the desire of young Latin American immunologists to bring state-of-the-art advances in diagnosis and treatment to their patients. The encouraging experience gained from years of successful collaborative efforts allows LASID to look with great optimism to its future.

**Africa and Middle East**

PID diagnosis and care in Africa and the Middle East has developed tremendously over the past 2 years, but major efforts are still needed, especially in Sub-Saharan Africa.

Indeed, we have witnessed the creation of PID networks and the release of multicentre studies on these conditions. In particular, two workshops bringing together experts from the North Africa and Middle East were held in Athens in 2012 and in Dubai in 2013. These led to the sharing of solutions between experts and to the building of cooperative bridges in training and research. In 2011, Ridha Barhouche and colleagues published a profile of PIDs in North Africa (Morocco, Tunisia and Egypt),\textsuperscript{10} while Saleh Al Muhsen and colleagues published on
the epidemiology of PID in the Middle East. Both regions are characterised by high rates of in-breeding (20–60%) and they have a comparable distribution of PID causes, with a high incidence of SCID and founder mutations. Teams in the Middle East, including Saudi Arabia, have published excellent results on HSCT and have contributed to internationals research on PID specific cases. PID treatment has been slower to develop in North Africa, with difficulties existing in IVIG access and HSCT being introduced only timidly.

These advances allow high hopes for patients with PIDs in the aforementioned regions. However, with the exception of South Africa — where the situation is comparable to that in North Africa — progress is lagging in the rest of the African countries. Indeed, there seems to be little or no activity in the PID field in over 40 of the 54 countries of this continent. To address this issue, the African Society for Immunodeficiencies (ASID), created in Casablanca in 2008, opted for regional actions to educate paediatricians and other healthcare professionals and to promote cross-country initiatives to allow the exchange of expert experience and education. ASID’s achievements are already palpable: Africa has a spokesperson for PID scientific and social societies, and schools to provide education about PIDs have involved a dozen countries in each region of Africa.

However, challenges remain in Africa, whose population has this year exceeded 1 billion citizens, and urgent international actions are necessary in this continent. These should aim not only to increase awareness of PIDs among physicians, nurses and other healthcare professionals, but in particular to bring the attention of the authorities and the general public to this large group of rare diseases and their significant effect on infant mortality. Indeed, PIDs are more common than is generally thought. It is estimated that up to 900,000 people in Africa may have a PID, whereas only around 1000 cases are currently registered.

The two regions of North Africa and the Middle East have rightly decided to work together to improve PID diagnosis and care. Corresponding joint efforts are also needed in the rest of Africa to enable the work of patient groups, doctors and nurses to bring a positive change for PID patients.
Australia

There is an active immunodeficiency community in Australia, with many of the major interactions revolving around the PID Committee of the Australasian Society of Clinical Immunology and Allergy (ASCIA) and the now well-established triennial Asia Pacific Primary Immune Deficiency (APPID) Summer School. While geographical constraints make large PID centres difficult to envisage, there are a number of major centres seeing patients with complex immunodeficiency disorders and the first Australian Jeffrey Modell Foundation Center will soon open at Sydney Children's Hospital, Randwick. The outcomes amongst the five centres currently performing HSCT for PIDs in Australia compare favourably to those from other parts of the world.14

From a research perspective there has been an effort to form collaborative research partnerships across the country, initially through the Australian PID registry15 and more recently through the antibody deficiency orientated Australia and New Zealand Antibody Deficiency Allele (ANZADA) study, which has now being joined by the more paediatric-orientated CIRCA group.

As in other (but not all) countries with similar economies, IVIG use is increasing by more than 10% per annum. In Australia most IVIG use is funded by the federal government16 and distributed through the Red Cross Blood Service. A study in New South Wales is interrogating the Red Cross database to improve our understanding of the factors driving these changes. Subcutaneous immunoglobulin (SCIG) is becoming increasingly popular among PID patients. SCIG appears to require lower overall immunoglobulin doses and some centres report that more patients are now using SCIG rather than IVIG. Although three products have been approved by regulatory authorities for SCIG use, and SCIG has been endorsed in the Australian criteria for the clinical use of immunoglobulin ([http://www.nba.gov.au/ivig/index.html](http://www.nba.gov.au/ivig/index.html)), national funding of SCIG use is still awaited.
Conclusion

The last 10 years has seen an unprecedented improvement in PID care in many areas of the world, including some areas where provision was seriously lacking. These improvements have resulted from collaborative efforts involving immunologists, non-specialist physicians, nurses’ associations, health providers, policymakers, and patient organisations. Such collaborations offer a model for further efforts to promote early diagnosis and therapy in order to extend and improve the lives of people with PIDs, especially in areas of greatest need.

References


